Report cover image

South America CIN & HR-HPV Treatment Market Forecast to 2028 - Regional Analysis - by Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Oth

Publisher The Insight Partners
Published Jun 09, 2023
Length 97 Pages
SKU # TIP18215712

Description

South America CIN & HR-HPV Treatment Market Forecast to 2028- Regional Analysis- by Disease Type (Cervical Intraepithelial Neoplasia 1, Cervical Intraepithelial Neoplasia 2, and Cervical Intraepithelial Neoplasia 3), Strain Type (HPV 16, HPV 18, and Others), Offering (Diagnostic Method and Treatment), Product Type (Kits & Reagents, Instruments, and Services), and End User (Hospitals & Clinics, Diagnostic Laboratories, Specialized Clinical Laboratories, and Others)


The South America CIN & HR-HPV treatment market is expected to grow from US$ 490.90 million in 2023 to US$ 659.12 million by 2028. It is estimated to grow at a CAGR of 6.1% from 2023 to 2028.

Favorable Initiatives for Preventing Cervical Cancer is Fueling South America CIN & HR-HPV treatment market

In August 2020, the World Health Organization (WHO) devised a strategy for the elimination of cervical cancer. Per this strategy, all countries across the region must focus on reaching and maintaining an incidence rate of less than 4 per 100,000 women to eliminate cervical cancer. To attain such low incidence rates, countries should focus on cervical cancer screening, treatment, and vaccination. Medicare, a popular government insurance program, provides coverage for PAP tests, pelvic exams, and clinical breast examinations performed every two years for cervical cancer screening.

Unitaid, a global health agency that works to bring about innovative solutions to prevent, diagnose, and treat major diseases in low- and middle-income countries, has come up with a new initiative for cervical cancer prevention. Its efforts are focused on expanding access to critical tools and services to screen for the early signs of cervical cancer, followed by the treatment of positive cases. Unitaid is providing support for the Clinton Health Access Initiative (CHAI) and the Scale Up Cervical Cancer Elimination with Secondary Prevention Strategy (SUCCESS) Project, which are being carried out in partnership with Expertise France, Jhpiego, and the Union for International Cancer Control (UICC). Unitaid is collaborating with these partners and governments of 14 low- and middle-income countries to develop an affordable and highly effective package of tools, which can help the World Health Organization achieve its cervical cancer elimination targets. The Unitaid has invested ~US$ 70 million in innovative tools to screen women living in low-resource environments for precancer conditions and treat them. In 14 countries, Unitaid is striving to overcome access barriers and laying the groundwork for national cervical cancer elimination efforts, demonstrating effective models of prevention across low- and middle-income countries.

Such initiatives by various healthcare organizations and governments for preventing cervical cancer boost the growth of the CIN & HR-HPV treatment market.

South America CIN & HR-HPV Treatment Market Overview

The South America CIN and HR-HPV Treatment market is segmented into Argentina, Brazil, and the Rest of South & Central America. The market growth in this region is attributed to the increasing prevalence of cervical cancer caused by HR-HPV infections and surging initiatives by governments to eliminate cervical cancers.

Exhibit: South America CIN & HR-HPV Treatment Market Revenue and Forecast to 2028 (US$ Million)

South America CIN & HR-HPV Treatment Market Segmentation

The South America CIN & HR-HPV treatment market is segmented into disease type, strain type, offering, product type, end user, and country.

Based on disease type, the market is segmented into cervical intraepithelial neoplasia 1 (CIN 1), cervical intraepithelial neoplasia 2 (CIN 2), and cervical intraepithelial neoplasia 3 (CIN 3). The cervical intraepithelial neoplasia 3 (CIN 3) segment registered the largest market share in 2023.

Based on strain type, the market is segmented into HPV 16, HPV 18, and others. The HPV 16 segment held the largest market share in 2023.

Based on offering, the market is bifurcated into diagnostic methods and treatments. The treatments segment held a larger market share in 2023. Further, diagnostic methods are segmented into pap smear, HPV testing, colposcopy, and biopsy. Further, treatments are bifurcated into excision surgery and ablation techniques.

Based on product type, the market is segmented into kits & reagents, instruments, and services. The services segment held the largest market share in 2023.

Based on end user, the market is segmented into hospitals & clinics, diagnostic laboratories, specialized clinical laboratories, and others. The hospitals & clinics segment held the largest market share in 2023.

Based on country, the market is segmented into Brazil Argentina, and the Rest of South America. Brazil dominated the market share in 2023.

Fujirebio Europe NV; Qiagen NV; Abbott Laboratories; F. Hoffmann-LA Roche Ltd; and Thermo Fisher Scientific Inc are the leading companies operating in the CIN & HR-HPV treatment market in the region.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South America CIN & HR-HPV treatment market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the South America CIN & HR-HPV treatment market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth South America market trends and outlook coupled with the factors driving the CIN & HR-HPV treatment market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table of Contents

97 Pages
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 South America CIN & HR-HPV Market – by Disease Type
1.3.2 South America CIN & HR-HPV Market – by Strain Type
1.3.3 South America CIN & HR-HPV Market – by Offering
1.3.4 South America CIN & HR-HPV Market – by Product Type
1.3.5 South America CIN & HR-HPV Market – by End User
1.3.6 South America CIN & HR-HPV Market – by Country
2. CIN & HR-HPV Treatment Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. South America CIN & HR-HPV Market – Market Landscape
4.1 Overview
4.2 PEST Analysis
4.2.1 4.2.1 South America PEST Analysis
4.3 Expert’s Opinion
5. South America CIN & HR-HPV Treatment Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Increase in Prevalence of Human Papillomavirus Infections
5.1.2 Favorable Initiatives for Preventing Cervical Cancer
5.2 Market Restraints
5.2.1 Increased Reoccurrence Rate and High Cost of CIN & HR-HPV Treatment
5.3 Market Opportunities
5.3.1 Development and Launch of Innovative Products
5.4 Future Trends
5.4.1 Use of Modern Technologies in CIN & HR-HPV Screening and Diagnosis
5.5 Impact Analysis
6. CIN & HR-HPV Market – South America Analysis
6.1 South America CIN & HR-HPV Market Revenue Forecast and Analysis
7. South America CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028– by Disease Type
7.1 Overview
7.2 South America CIN and HR-HPV Treatment Market, By disease type, 2022 & 2028 (%)
7.3 CIN 1
7.3.1 Overview
7.3.2 CIN 1: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
7.4 CIN 2
7.4.1 Overview
7.4.2 CIN 2: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
7.5 CIN 3
7.5.1 Overview
7.5.2 CIN 3: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
8. South America CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028– by Strain Type
8.1 Overview
8.2 South America CIN and HR-HPV Treatment Market, By Strain Type, 2022 & 2028 (%)
8.3 HPV 16
8.3.1 Overview
8.3.2 HPV 16: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
8.4 HPV 18
8.4.1 Overview
8.4.2 HPV 18: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9. South America CIN and HR-HPV Treatment Market Revenue and Forecasts To 2028– by Offering
9.1 Overview
9.2 South America CIN and HR-HPV Treatment Market, By Offering, 2022 & 2028 (%)
9.4 Diagnostic Method
9.4.1 Overview
9.4.2 Diagnostic Method: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.3 Pap Smear
9.4.3.1 Overview
9.4.3.2 Pap Smear: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.4 HPV Testing
9.4.4.1 Overview
9.4.4.2 HPV Testing: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.5 Colposcopy
9.4.5.1 Overview
9.4.5.2 Colposcopy: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.4.6 Biopsy
9.4.6.1 Overview
9.4.6.2 Biopsy: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.5 Treatment
9.5.1 Overview
9.5.2 Treatment: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.5.2.1 Excision Surgery
9.5.2.1.1 Overview
9.5.2.1.2 Excision Surgery: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
9.5.2.2 Ablation Techniques
9.5.2.2.1 Overview
9.5.2.2.2 Ablation Techniques: CIN and HR-HPV Treatment Market Revenue and Forecasts to 2028 (US$ Million)
10. South America CIN & HR-HPV Treatment Market Analysis and Forecast to 2028 – by Product Type
10.1 Overview
10.2 South America CIN & HR-HPV Treatment Market, by Product Type 2022 & 2028 (%)
10.3 Kits & Reagents
10.3.1 Overview
10.3.2 Kits & Reagents: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
10.4 Instrument
10.4.1 Overview
10.4.2 Instrument: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
10.5 Services
10.5.1 Overview
10.5.2 Services: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11. South America CIN & HR-HPV Treatment Market Analysis and Forecast to 2028 – by End User
11.1 Overview
11.2 South America CIN & HR-HPV Treatment Market, by End User 2022 & 2028 (%)
11.3 Hospital & Clinics
11.3.1 Overview
11.3.2 Hospital & Clinics: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.4 Diagnostic Laboratories
11.4.1 Overview
11.4.2 Diagnostic Laboratories: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.5 Specialized Clinical Laboratories
11.5.1 Overview
11.5.2 Specialized Clinical Laboratories: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
11.6 Others
11.6.1 Overview
11.6.2 Others: CIN & HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12. South America CIN & HR-HPV Treatment Market Revenue and Forecasts to 2028 – Country Analysis
12.1 South America CIN & HR-HPV Market
12.1.1 Overview
12.1.1.1 Argentina: CIN and HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.1 Overview
12.1.1.1.2 Argentina CIN and HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.1.1.3 Argentina CIN and HR-HPV Treatment Market, by Disease Type, 2019–2028 (US$ Million)
12.1.1.1.4 Argentina CIN and HR-HPV Treatment Market, by Strain Type, 2019–2028 (US$ Million)
12.1.1.1.5 Argentina CIN and HR-HPV Treatment Market, by Offerings, 2019–2028 (US$ Million)
12.1.1.1.5.1 Argentina: CIN and HR-HPV Treatment Market, by Diagnostic Methods, 2019–2028 (US$ Million)
12.1.1.1.5.2 Argentina: CIN and HR-HPV Treatment Market, by Treatments, 2019–2028 (US$ Million)
12.1.1.1.6 Argentina CIN and HR-HPV Treatment Market, by Product Type, 2019–2028 (US$ Million)
12.1.1.1.7 Argentina CIN and HR-HPV Treatment Market, by End Users, 2019–2028 (US$ Million)
12.1.1.2 Brazil: CIN and HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.1 Overview
12.1.1.2.2 Brazil CIN and HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.1.2.3 Brazil CIN and HR-HPV Treatment Market, by Disease Type, 2019–2028 (US$ Million)
12.1.1.2.4 Brazil CIN and HR-HPV Treatment Market, by Strain Type, 2019–2028 (US$ Million)
12.1.1.2.5 Brazil CIN and HR-HPV Treatment Market, by Offerings, 2019–2028 (US$ Million)
12.1.1.2.5.1 Brazil: CIN and HR-HPV Treatment Market, by Diagnostic Methods, 2019–2028 (US$ Million)
12.1.1.2.5.2 Brazil: CIN and HR-HPV Treatment Market, by Treatments, 2019–2028 (US$ Million)
12.1.1.2.6 Brazil CIN and HR-HPV Treatment Market, by Product Type, 2019–2028 (US$ Million)
12.1.1.2.7 Brazil CIN and HR-HPV Treatment Market, by End Users, 2019–2028 (US$ Million)
12.1.1.3 Rest of South America: CIN and HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.1 Overview
12.1.1.3.2 Rest of South America CIN and HR-HPV Treatment Market – Revenue and Forecast to 2028 (US$ Million)
12.1.1.3.3 Rest of South America CIN and HR-HPV Treatment Market, by Disease Type, 2019–2028 (US$ Million)
12.1.1.3.4 Rest of South America CIN and HR-HPV Treatment Market, by Strain Type, 2019–2028 (US$ Million)
12.1.1.3.5 Rest of South America CIN and HR-HPV Treatment Market, by Offerings, 2019–2028 (US$ Million)
12.1.1.3.5.1 Rest of South America: CIN and HR-HPV Treatment Market, by Diagnostic Methods, 2019–2028 (US$ Million)
12.1.1.3.5.2 Rest of South America: CIN and HR-HPV Treatment Market, by Treatments, 2019–2028 (US$ Million)
12.1.1.3.6 Rest of South America CIN and HR-HPV Treatment Market, by Product Type, 2019–2028 (US$ Million)
12.1.1.3.7 Rest of South America CIN and HR-HPV Treatment Market, by End Users, 2019–2028 (US$ Million)
13. South America CIN & HR-HPV Treatment Market – Industry Landscape
13.1 Overview
13.2 Growth Strategies in CIN & HR-HPV Treatment Market
13.3 Organic Growth Strategies
13.3.1 Overview
13.4 Inorganic Growth Strategies
13.4.1 Overview
14. Company Profiles
14.1 Fujirebio Europe NV
14.1.1 Key Facts
14.1.2 Business Description
14.1.3 Products and Services
14.1.4 Financial Overview
14.1.5 SWOT Analysis
14.1.6 .Key Developments
14.2 Qiagen NV
14.2.1 Key Facts
14.2.2 Business Description
14.2.3 Products and Services
14.2.4 Financial Overview
14.2.5 SWOT Analysis
14.2.6 Key Developments
14.3 Abbott Laboratories
14.3.1 Key Facts
14.3.2 Business Description
14.3.3 Products and Services
14.3.4 Financial Overview
14.3.5 SWOT Analysis
14.3.6 Key Developments
14.4 F. Hoffmann-La Roche Ltd
14.4.1 Key Facts
14.4.2 Business Description
14.4.3 Products and Services
14.4.4 Financial Overview
14.4.5 SWOT Analysis
14.4.6 Key Developments
14.5 Thermo Fisher Scientific Inc
14.5.1 Key Facts
14.5.2 Business Description
14.5.3 Products and Services
14.5.4 Financial Overview
14.5.5 SWOT Analysis
14.5.6 Key Developments
15. Appendix
15.1 About The Insight Partners
15.2 Glossary of Terms
LIST OF TABLES
Table 1. Argentina CIN and HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 2. Argentina CIN and HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 3. Argentina CIN and HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 4. Argentina CIN and HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million
Table 5. Argentina CIN and HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million
Table 6. Argentina CIN and HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 7. Argentina CIN and HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 8. Brazil CIN and HR-HPV Treatment Market, by Disease type – Revenue and Forecast to 2028 (US$ Million)
Table 9. Brazil CIN and HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 10. Brazil CIN and HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 11. Brazil CIN and HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million
Table 12. Brazil CIN and HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million
Table 13. Brazil CIN and HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 14. Brazil CIN and HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 15. Rest of South America CIN and HR-HPV Treatment Market, by Disease Type – Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of South America CIN and HR-HPV Treatment Market, by Strain Type – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of South America CIN and HR-HPV Treatment Market, by Offerings – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of South America CIN and HR-HPV Treatment Market, by Diagnostic Methods – Revenue and Forecast to 2028 (US$ Million
Table 19. Rest of South America CIN and HR-HPV Treatment Market, by Treatments – Revenue and Forecast to 2028 (US$ Million
Table 20. Rest of South America CIN and HR-HPV Treatment Market, by Product Type – Revenue and Forecast to 2028 (US$ Million)
Table 21. Rest of South America CIN and HR-HPV Treatment Market, by End Users – Revenue and Forecast to 2028 (US$ Million)
Table 22. Recent Organic Growth Strategies in CIN & HR-HPV Treatment Market
Table 23. Recent Inorganic Growth Strategies in the CIN & HR-HPV Treatment Market
Table 24. Glossary of Terms
LIST OF FIGURES

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us